Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.
Trends Pharmacol Sci. 2021 Apr;42(4):255-267. doi: 10.1016/j.tips.2021.01.003. Epub 2021 Feb 6.
Currently, there are about 7000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases. Although drug repurposing is not novel, new strategies have been developed in recent years to do it in a systematic and rational way. Here, we review applied methodologies, recent accomplished progress, and the challenges associated in drug repurposing for rare diseases.
目前,约有 7000 种已确认的罕见病,共同影响着 10%的人口。然而,所有罕见病中只有不到 6%有经过批准的治疗方案,这凸显了它们在药物开发方面的巨大未满足需求。与开发新的孤儿药相比,将药物重新用于新适应症是一种节省时间和成本效益高的方法,成功率更高,因此可以大大降低罕见病药物开发的风险。尽管药物重定位并不新颖,但近年来已经开发出了新的策略,以系统和合理的方式进行药物重定位。在这里,我们综述了用于罕见病药物重定位的应用方法学、最新进展和相关挑战。